Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Key Points
Key points are not available for this paper at this time.
Abstract
Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease.
Gebretekle et al. (Tue,) studied this question.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants2020 · 737 citations